` 600332 (Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

600332
vs
S
Shanghai Composite

Over the past 12 months, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd has underperformed Shanghai Composite, delivering a return of -8% compared to the Shanghai Composite's +23% growth.

Stocks Performance
600332 vs Shanghai Composite

Loading
600332
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
600332 vs Shanghai Composite

Loading
600332
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
600332 vs Shanghai Composite

Loading
600332
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd vs Peers

Shanghai Composite
600332
JEF
JNJ
4312
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View

Market Cap
40.4B CNY
Industry
Pharmaceuticals

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. stands as a prominent player in China's healthcare industry, weaving a rich legacy that dates back to its formation in the 20th century. Rooted in the dynamic city of Guangzhou, Baiyunshan reflects a harmonious blend of traditional Chinese medicine (TCM) and modern pharmaceutical innovation. The company's name itself, Baiyunshan—meaning "White Cloud Mountain" in Chinese—symbolizes its foundational connection to the city's cultural heritage and its aspiration to elevate healthcare standards. Baiyunshan's operations are a testament to its multifaceted approach to pharmaceutical production. It delves into the research and development, manufacturing, and distribution of both TCM and Western medicine. This dual approach enables Baiyunshan to cater to a diverse demographic, forging a unique path by merging ancient medical wisdom with cutting-edge scientific advancements. The core of Baiyunshan's business strategy pivots around its expansive product portfolio, which is instrumental in its revenue generation. Pharmaceuticals are at its heart, encompassing a wide range of products from patent medicines to essential drugs that are household names in China. Additionally, the company has successfully branched into the production of over-the-counter (OTC) products, health supplements, and even skincare products, broadening its consumer reach. Meanwhile, Baiyunshan's distribution network—extensive and strategically aligned—stretches across domestic and international markets, ensuring its products are widely accessible. By leveraging strategic partnerships and ongoing innovation, the company continually fortifies its market presence, making Baiyunshan a notable financial performer and a beacon of trust in the healthcare industry.

Intrinsic Value
27.75 CNY
Undervaluation 10%
Intrinsic Value
Price
Back to Top